These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32101383)

  • 1. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and
    Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
    ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
    Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
    Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays.
    Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V
    Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
    Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
    Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
    De Luca MA; Castelli MP; Loi B; Porcu A; Martorelli M; Miliano C; Kellett K; Davidson C; Stair JL; Schifano F; Di Chiara G
    Neuropharmacology; 2016 Jun; 105():630-638. PubMed ID: 26686391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.
    Glatfelter GC; Partilla JS; Baumann MH
    Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity profiling of Cumyl-PEGACLONE variants at the CB
    Janssens L; Cannaert A; Connolly MJ; Liu H; Stove CP
    Drug Test Anal; 2020 Sep; 12(9):1336-1343. PubMed ID: 32490586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD
    Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
    Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
    ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
    Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
    J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.
    Finlay DB; Nguyen T; Gamage TF; Chen S; Barrus DG; Patel PR; Thomas BF; Wiley JL; Zhang Y; Glass M
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00901. PubMed ID: 35041297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
    Wilson CD; Hiranita T; Fantegrossi WE
    Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.
    Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR
    Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.